Octenyl-succinylated inulins for the delivery of hydrophobic drug

Int J Biol Macromol. 2022 Nov 30:221:1112-1120. doi: 10.1016/j.ijbiomac.2022.09.068. Epub 2022 Sep 12.

Abstract

The efficacy of hydrophobic anticancer drugs is limited by their poor solubility in water, inefficient target delivery, and toxic side effects. In this work, doxorubicin (DOX) was solubilized using OSA-inulins which created micellar aggregates in aqueous solution above a critical concentration. In vitro delivery of OSA-inulin-DOX micelles resulted in strong inhibition of the growth of MCF-7 breast cancer cells as compared to free DOX. They also displayed a faster cellular uptake rate, indicating that the micelles were promptly internalized into the cells through CD44 receptor-mediated endocytosis. During in vivo tumor suppression experiments in tumor-bearing mice, the OSA-inulin-DOX micelles strongly hindered tumor growth and showed substantially lower systemic toxicity compared with free DOX. Our achievements demonstrate that OSA-inulin has great potential for the encapsulating, dissolving, and targeted delivery of hydrophobic drugs, especially antitumor drugs, for nutraceutical, medical, and pharmaceutical applications.

Keywords: Encapsulation; Octenyl-succinylated inulin; Release.

MeSH terms

  • Animals
  • Antineoplastic Agents* / chemistry
  • Doxorubicin / chemistry
  • Drug Delivery Systems
  • Humans
  • Inulin
  • MCF-7 Cells
  • Mice
  • Micelles*

Substances

  • Micelles
  • Inulin
  • Doxorubicin
  • Antineoplastic Agents